KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Seltoplasmid promotes ulcer healing versus placebo for treating patients with chronic limb-threatening ischemia: HOPE CLTI-2 trial.

Xiao Di, Changwei Liu, Siqiao Sun, Jinbao Qin, Xueli Guo, Yikuan Chen, Xin Li, Hongkun Zhang, Ming Liu, Liu Yang, Hui Zhao, Shaoying Lu, Jingyong Huang, Yunfeng Zhang, Jun Li, Xiaolei Lin, Kai Yao, Jingdong Tang, Jian Wang, Zhanfeng Gao, Jinjun Wang, Xiaojin Huang, Songshan Xu, Yue Liu, Wei Han, Leng Ni, Wei Ye, Yuehong Zheng, Yuexin Chen, Bao Liu

Mol Ther 33(7) 3423-3433

PMID40221835
PMCIDPMC12266034
DOI10.1016/j.ymthe.2025.04.009
发表日期2025-04-13
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Intramuscular injection of donaperminogene seltoplasmid (recombinant human hepatocyte growth factor plasmids) represents a gene therapy that treats patients with chronic limb-threatening ischemia (CLTI). The HOPE CLTI-2 trial was a phase 3, multicenter, double-blind, placebo-controlled study aimed to evaluate the efficacy and safety of seltoplasmid in patients with Rutherford class 5 CLTI. This study did not require participants to be ineligible for revascularization, allowing enrollment of patients with CLTI caused by either atherosclerosis (ASO) or Buerger disease (or thromboangiitis obliterans [TAO]). The primary endpoint was the complete ulcer healing rate at 6 months. A total of 242 participants (53.3% ASO versus 46.7% TAO) were enrolled, with 161 receiving seltoplasmid and 81 receiving placebo. Complete ulcer healing was achieved in 70 patients in the seltoplasmid group compared to 15 patients in the placebo group, resulting in an adjusted healing rate difference of 26.1% (95% confidence interval [CI]: 15.1%-37.0%; p < 0.001). The hazard ratio for healing was 2.31 (95% CI: 1.32-4.05; p = 0.004). The benefits of seltoplasmid on ulcer healing persisted in both TAO and ASO subgroups. Serious adverse events were rare. Our study demonstrated that seltoplasmid significantly improved ulcer healing rates in patients with Rutherford class 5 CLTI compared to placebo.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2 Kaplan-Meier curve of complete ulcer healing rate (full analysis set) Kaplan-Meier analyses for complete ulcer healing rate was performed using a time-dependent Cox regression analysis model to generate a hazard ratio adjusted for baseline ulcer size and comorbid diabetes. The p value was calculated against a two-sided alpha level of 0.05.

Figure_2

cumulative ulcer healing rate

Figure 2 · Panel Figure_2

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Figure_2 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 3

Figure 3 Kaplan-Meier curve of amputation-free survival (full analysis set) Kaplan-Meier analyses for amputation-free survival was performed using a time-dependent Cox regression analysis model to generate a hazard ratio adjusted for baseline ulcer size and comorbid diabetes. The p value was calculated against a two-sided alpha level of 0.05.

amputation-free_survival

amputation-free survival

Figure 3 · Panel amputation-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel amputation-free_survival 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1 Trial profile
非 KM Figure
Figure 4Figure 4 Forest plot illustrating subgroup analyses of complete ulcer healing rates Each error bar represents the 95% confidence interval of adjusted rate difference calculated using the Delta method. The analyses were adjusted for baseline ulcer area and comorbid diabetes. The p value was calculated against a one-sided alpha level of 0.025. ASO, atherosclerosis; ABI, ankle-brachial index; TAO, thromboangiitis obliterans.
非 KM Figure
Figure 5Figure 5 Design of study
非 KM Figure